sage therapeutics biogen - Search News

Sage, Biogen

news.bloomberglaw · 1h

Biogen Sued by Neuroscience Company Sage After Buyout Offer (1)

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the smaller neuroscience company for about $469 million.

Investing · 4d

Sage Therapeutics shares spike after Biogen offers to buy remaining stake

Investing.com - Shares in Sage Therapeutics (NASDAQ: SAGE) were more than 36% higher in premarket US trading on Monday, fueled by news that drugmaker Biogen (NASDAQ: BIIB) has proposed to buy all outstanding shares in the group it does not already own for $7.22 each.

MarketWatch · 4d

Sage Shares Surge Premarket After Biogen Proposes Takeover

Shares of Sage Therapeutics jumped nearly 40% in premarket trading Monday after the biopharmaceutical company received an unsolicited buyout bid from partner Biogen. Biogen, which already owns a roughly 10.

Investopedia on MSN · 4d

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

Key Takeaways Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.

2d

Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

4don MSN

Biogen Wants to Buy Its Partner Sage for Almost No Premium

Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01.

GlobalData on MSN3d

Biogen proposes acquisition of partner Sage Therapeutics

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum ...

Biogen Submits Offer to Buy Embattled Partner Sage

Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of ...

Biogen CEO confirms he’s shopping for biotechs: ‘We will be doing deals’

Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.

Biogen, already a Sage partner and equity owner, offers to buy the rest of the neuro biotech

A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...

Biogen offers to buy out wilting Sage for $442 million

The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...

2don MSN

Biogen CEO sees no burning need for more acquisitions

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

4d

BofA moves to No Rating on Sage Therapeutics after Biogen bid

BofA is moving to No Rating on Sage Therapeutics (SAGE) after the company announced it has received an unsolicited, nonbinding acquisition ...

BioPharma Dive4d

Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results